These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23140665)

  • 1. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity.
    Rook JM; Noetzel MJ; Pouliot WA; Bridges TM; Vinson PN; Cho HP; Zhou Y; Gogliotti RD; Manka JT; Gregory KJ; Stauffer SR; Dudek FE; Xiang Z; Niswender CM; Daniels JS; Jones CK; Lindsley CW; Conn PJ
    Biol Psychiatry; 2013 Mar; 73(6):501-9. PubMed ID: 23140665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism.
    Bridges TM; Rook JM; Noetzel MJ; Morrison RD; Zhou Y; Gogliotti RD; Vinson PN; Xiang Z; Jones CK; Niswender CM; Lindsley CW; Stauffer SR; Conn PJ; Daniels JS
    Drug Metab Dispos; 2013 Sep; 41(9):1703-14. PubMed ID: 23821185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Tool Compounds to Study Signaling Bias.
    Arsova A; Møller TC; Hellyer SD; Vedel L; Foster SR; Hansen JL; Bräuner-Osborne H; Gregory KJ
    Mol Pharmacol; 2021 May; 99(5):328-341. PubMed ID: 33602724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).
    Turlington M; Noetzel MJ; Chun A; Zhou Y; Gogliotti RD; Nguyen ED; Gregory KJ; Vinson PN; Rook JM; Gogi KK; Xiang Z; Bridges TM; Daniels JS; Jones C; Niswender CM; Meiler J; Conn PJ; Lindsley CW; Stauffer SR
    J Med Chem; 2013 Oct; 56(20):7976-96. PubMed ID: 24050755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential contribution of metabotropic glutamate receptor 5 common allosteric binding site residues to biased allosteric agonism.
    Sengmany K; Hellyer SD; Christopoulos A; Lapinsky DJ; Leach K; Gregory KJ
    Biochem Pharmacol; 2020 Jul; 177():114011. PubMed ID: 32380090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.
    Sengmany K; Singh J; Stewart GD; Conn PJ; Christopoulos A; Gregory KJ
    Neuropharmacology; 2017 Mar; 115():60-72. PubMed ID: 27392634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabotropic glutamate receptor 5 (mGlu
    Hellyer SD; Albold S; Sengmany K; Singh J; Leach K; Gregory KJ
    J Neurochem; 2019 Nov; 151(3):301-315. PubMed ID: 31376155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probe dependence and biased potentiation of metabotropic glutamate receptor 5 is mediated by differential ligand interactions in the common allosteric binding site.
    Hellyer SD; Sengmany K; Keller AN; Christopoulos A; Leach K; Gregory KJ
    Biochem Pharmacol; 2020 Jul; 177():114013. PubMed ID: 32389635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles.
    Rook JM; Tantawy MN; Ansari MS; Felts AS; Stauffer SR; Emmitte KA; Kessler RM; Niswender CM; Daniels JS; Jones CK; Lindsley CW; Conn PJ
    Neuropsychopharmacology; 2015 Feb; 40(3):755-65. PubMed ID: 25241804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy.
    Nickols HH; Yuh JP; Gregory KJ; Morrison RD; Bates BS; Stauffer SR; Emmitte KA; Bubser M; Peng W; Nedelcovych MT; Thompson A; Lv X; Xiang Z; Daniels JS; Niswender CM; Lindsley CW; Jones CK; Conn PJ
    J Pharmacol Exp Ther; 2016 Jan; 356(1):123-36. PubMed ID: 26503377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents.
    Rook JM; Xiang Z; Lv X; Ghoshal A; Dickerson JW; Bridges TM; Johnson KA; Foster DJ; Gregory KJ; Vinson PN; Thompson AD; Byun N; Collier RL; Bubser M; Nedelcovych MT; Gould RW; Stauffer SR; Daniels JS; Niswender CM; Lavreysen H; Mackie C; Conde-Ceide S; Alcazar J; Bartolomé-Nebreda JM; Macdonald GJ; Talpos JC; Steckler T; Jones CK; Lindsley CW; Conn PJ
    Neuron; 2015 May; 86(4):1029-1040. PubMed ID: 25937172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
    Parmentier-Batteur S; Hutson PH; Menzel K; Uslaner JM; Mattson BA; O'Brien JA; Magliaro BC; Forest T; Stump CA; Tynebor RM; Anthony NJ; Tucker TJ; Zhang XF; Gomez R; Huszar SL; Lambeng N; Fauré H; Le Poul E; Poli S; Rosahl TW; Rocher JP; Hargreaves R; Williams TM
    Neuropharmacology; 2014 Jul; 82():161-73. PubMed ID: 23291536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.
    Gregory KJ; Herman EJ; Ramsey AJ; Hammond AS; Byun NE; Stauffer SR; Manka JT; Jadhav S; Bridges TM; Weaver CD; Niswender CM; Steckler T; Drinkenburg WH; Ahnaou A; Lavreysen H; Macdonald GJ; Bartolomé JM; Mackie C; Hrupka BJ; Caron MG; Daigle TL; Lindsley CW; Conn PJ; Jones CK
    J Pharmacol Exp Ther; 2013 Nov; 347(2):438-57. PubMed ID: 23965381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAR studies on mGlu5 receptor positive allosteric modulators (2003- 2013).
    Hao J; Xiong H
    Curr Top Med Chem; 2014; 14(15):1789-841. PubMed ID: 25176124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling.
    Noetzel MJ; Gregory KJ; Vinson PN; Manka JT; Stauffer SR; Lindsley CW; Niswender CM; Xiang Z; Conn PJ
    Mol Pharmacol; 2013 Apr; 83(4):835-47. PubMed ID: 23348500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding.
    Butkiewicz M; Rodriguez AL; Rainey SE; Wieting J; Luscombe VB; Stauffer SR; Lindsley CW; Conn PJ; Meiler J
    ACS Chem Neurosci; 2019 Aug; 10(8):3427-3436. PubMed ID: 31132237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.
    Sengmany K; Hellyer SD; Albold S; Wang T; Conn PJ; May LT; Christopoulos A; Leach K; Gregory KJ
    Neuropharmacology; 2019 May; 149():83-96. PubMed ID: 30763654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.
    Noetzel MJ; Rook JM; Vinson PN; Cho HP; Days E; Zhou Y; Rodriguez AL; Lavreysen H; Stauffer SR; Niswender CM; Xiang Z; Daniels JS; Jones CK; Lindsley CW; Weaver CD; Conn PJ
    Mol Pharmacol; 2012 Feb; 81(2):120-33. PubMed ID: 22021324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.
    Dogra S; Conn PJ
    Mol Pharmacol; 2022 May; 101(5):275-285. PubMed ID: 35246479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biased agonism and allosteric modulation of metabotropic glutamate receptor 5.
    Trinh PNH; May LT; Leach K; Gregory KJ
    Clin Sci (Lond); 2018 Nov; 132(21):2323-2338. PubMed ID: 30389826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.